Resultados globales: 9 registros encontrados en 0.02 segundos.
Artículos, Encontrados 5 registros
Documentos de investigación, Encontrados 4 registros
Artículos Encontrados 5 registros  
1.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, Sandra (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (NKI) (Netherlands)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratù, Ginevra (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
2.
11 p, 542.8 KB A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer / Reynolds, Kerry Lynn ; Bedard, Philippe L. (Toronto, ON Canada) ; Lee, Se-Hoon (Seoul, Republic of Korea) ; Lin, Chia-Chi (Taipei, Taiwan) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Alsina, Maria (Hospital Universitari Vall d'Hebron) ; Cohen, Ezra (La Jolla, CA USA) ; Baselga Torres, Josep, 1959-2021, (New York, NY USA) ; Blumenschein, George (Houston, TX USA) ; Graham, Donna M. (Toronto, ON Canada) ; Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ; Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ; Sharma, Sunil (Salt Lake City, UT USA) ; Salgia, Ravi (Duarte, CA USA) ; Seroutou, Abdelkader (Basel, Switzerland) ; Tian, Xianbin (East Hanover, NJ USA) ; Fernandez, Rose (East Hanover, NJ USA) ; Morozov, Alex (New York, NY USA) ; Sheng, Qing (Cambridge, MA USA) ; Ramkumar, Thiruvamoor (East Hanover, NJ USA) ; Zubel, Angela (Basel, Switzerland) ; Bang, Yung-Jue (Seoul, Republic of Korea) ; Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)  
3.
39 p, 4.7 MB mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer / Zabala-Letona, Amaia (Centro de Investigación Biomédica en Red de Cáncer) ; Arruabarrena Aristorena, Amaia (CIC bioGUNE) ; Martín Martín, Natalia (Centro de Investigación Biomédica en Red de Cáncer) ; Fernández Ruiz, Sonia (Centro de Investigación Biomédica en Red de Cáncer) ; Sutherland, James D. (CIC bioGUNE) ; Clasquin, Michelle (AGIOS Pharmaceuticals) ; Tomás Cortázar, Julen (CIC bioGUNE) ; Jiménez, José (Hospital Universitari Vall d'Hebron) ; Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ; Quang, Phong (AGIOS Pharmaceuticals) ; Ximénez Embun, Pilar (Centro Nacional de Investigaciones Oncológicas) ; Bago, Ruzica (MRC Protein Phosphorylation and Ubiquitylation Unit) ; Ugalde Olano, Aitziber (Hospital de Basurto (Bilbao, Biscaia)) ; Loizaga Iriarte, Ana (Hospital de Basurto (Bilbao, Biscaia)) ; Lacasa Viscasillas, Isabel (Hospital de Basurto (Bilbao, Biscaia)) ; Unda, Miguel (Hospital de Basurto (Bilbao, Biscaia)) ; Torrano, Verónica (Centro de Investigación Biomédica en Red de Cáncer) ; Cabrera, Diana (CIC bioGUNE) ; van Liempd, Sebastiaan M. (CIC bioGUNE) ; Cendon, Ylenia (Universidad Autónoma de Madrid) ; Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ; Murray, Stuart (AGIOS Pharmaceuticals) ; Revandkar, Ajinkya (University of Lausanne) ; Alimonti, Andrea (University of Lausanne) ; Zhang, Yinan (Harvard School of Public Health) ; Barnett, Amelia (AGIOS Pharmaceuticals) ; Lein, Gina (AGIOS Pharmaceuticals) ; Pirman, David (AGIOS Pharmaceuticals) ; Cortázar, Ana R. (CIC bioGUNE) ; Arreal, Leire (CIC bioGUNE) ; Prudkin, Ludmila (Hospital Universitari Vall d'Hebron) ; Astobiza, Ianire (CIC bioGUNE) ; Valcárcel Jiménez, Lorea (CIC bioGUNE) ; Zúñiga García, Patricia (CIC bioGUNE) ; Fernández Domínguez, Itziar (CIC bioGUNE) ; Piva, Marco (CIC bioGUNE) ; Caro-Maldonado, Alfredo (CIC bioGUNE) ; Sánchez Mosquera, Pilar (CIC bioGUNE) ; Castillo Martín, Mireia (Fundação Champalimaud) ; Serra, Violeta (Hospital Universitari Vall d'Hebron) ; Beraza, Naiara (CIC bioGUNE) ; Gentilella, Antonio (Institut Català d'Oncologia) ; Thomas, George (Institut Català d'Oncologia) ; Azkargorta, Mikel (Carlos III Networked Proteomics Platform) ; Elortza, Felix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Farràs, Rosa (Centro de Investigación Príncipe Felipe (València)) ; Olmos, David (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Efeyan, Alejo (Centro Nacional de Investigaciones Oncológicas) ; Anguita, Juan (Ikerbasque) ; Muñoz, Javier (Carlos III Networked Proteomics Platform) ; Falcón Pérez, Juan M. (Ikerbasque) ; Barrio, Rosa (CIC bioGUNE) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Mato, José M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Martínez Chantar, Maria L. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Cordon Cardo, Carlos (Icahn School of Medicine at Mount Sinai) ; Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Marks, Kevin (AGIOS Pharmaceuticals) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Manning, Brendan D. (Harvard School of Public Health) ; Marjon, Katya (AGIOS Pharmaceuticals) ; Carracedo, Arkaitz (University of the Basque Country) ; Universitat Autònoma de Barcelona
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. [...]
2017 - 10.1038/nature22964
Nature, Vol. 547 (July 2017) , p. 109-113  
4.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ; Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M. (Eli Lilly and Company) ; Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  
5.
6 p, 263.8 KB A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer / Tan, E.H. (National Cancer Centre (Singapur). Department of Medical Oncology) ; Ramlau, R. (Regional Lung Disease Centre (Poznan). Department of Oncology) ; Pluzanska, A. (Regional Oncology Centre (Lodz, Polònia). Oncological Chemotherapy Clinic) ; Kuo, H. -P. (Chang Gung Memorial Hospital (Linkou, Taiwan). Department of Thoracic Medicine) ; Reck, M. (Hospital Grosshansdorf (Grosshansdorf, Alemanya). Department of Thoracic Oncology) ; Milanowski, J. (Akademia Medyczna w Lublinie (Lublin, Polònia). Department of Pneumology, Oncology and Allergology) ; Au, J. S. -K. (Queen Elizabeth Hospital (Hong Kong). Department of Clinical Oncology) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Yang, P. -C. (National Taiwan University Hospital (Taipei, Taiwan)) ; Damyanov, D. (Specialized Hospital for Active Treatment in Oncology (Sofia, Bulgaria)) ; Orlov, S. (Pavlov State Medical University. Research Institute of Pulmonology (Sant Petersburg, Rússia)) ; Akimov, M. (Hoffmann-La Roche (Basel, Suïssa)) ; Delmar, P. (Hoffmann-La Roche (Basel, Suïssa)) ; Essioux, L. (Hoffmann-La Roche (Basel, Suïssa)) ; Hillenbach, C. (Hoffmann-La Roche (Basel, Suïssa)) ; Klughammer, B. (Hoffmann-La Roche (Basel, Suïssa)) ; McLoughlin, P. (Hoffmann-La Roche (Basel, Suïssa)) ; Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron)
Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. [...]
2010
Annals of oncology, Vol. 21, Issue 2 (2010) , p. 217-222  

Documentos de investigación Encontrados 4 registros  
1.
347 p, 6.8 MB Evaluación del perfil hormonal en pacientes con cáncer de mama precoz sometidas a hormonoterapia adyuvante / Bellet Ezquerra, Meritxell ; Cortés, Javier, dir. ; Ruiz, Isabel, (Ruiz Camps) dir. ; Baselga Torres, Josep, 1959-2021, dir. ; Universitat Autònoma de Barcelona. Departament de Medicina
La presente tesis se basa en el subestudio SOFT-EST, que se realizó en el marco de un ensayo clínico fase III adyuvante internacional para pacientes premenopáusicas con cáncer de mama (CM) precoz receptor hormonal positivo (estudio SOFT). [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2016  
2.
96 p, 1.0 MB Aportación de los estudios farmacodinámicos en el desarrollo de tratamientos dirigidos contra dianas moleculares de cascadas de señalización proliferativas / Tabernero, Josep ; Baselga Torres, Josep, 1959-2021, dir. (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona. Departament de Medicina
Esta tesis doctoral se ha realizado por compendio de publicaciones de dos estudios fase I desarrollados en el servicio de Oncología del Hospital Vall d'Hebron, de la Universitat Autònoma de Barcelona, en Barcelona, España. [...]
This doctoral thesis has been written on the basis of two publications of two phase I studies developed at the Medical Oncology Department at the Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2013  
3.
132 p, 3.3 MB Development and validation of predictive model for identification of MLH1 and MSH2 mutation carriers in Lynch syndrome / Balmaña Gelpí, Judith ; Brunet, Joan (dir.) ; Baselga Torres, Josep, 1959-2021, dir. (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona. Departament de Medicina
Lynch syndrome is the most frequent hereditary colorectal cancer syndrome. It is estimated to account for 1-3% of all colorectal cancer patients and endometrial cancer patients14. Many studies have been published to attempt to address the prevalence of this syndrome and the heterogeneity is huge, mostly because population-based studies are few, geographical distribution of carriers may differ due to founder mutations, or studies may include testing of different type of mismatch repair (MMR) genes15-28. [...]
Bellaterra : Universitat Autònoma de Barcelona, 2010  
4.
80 p, 310.3 KB Telomerasa : regulación, diana terapéutica y significado clínico en neoplasias humanas / Albanell, Joan ; Baselga Torres, Josep, 1959-2021, dir. (Hospital Universitari Vall d'Hebron) ; Moore, Malcolm A. S., dir.
Las células malignas deben adquirir un potencial de replicación ilimitado (inmortalidad celular) para la formación de tumores avanzados. La adquisición de inmortalidad celular depende de la reactivación de la telomerasa, una enzima que permite compensar el problema de replicación terminal del ADN asociado a cada división celular. [...]
Malignant cells have to acquire a limitless replicative potential (immortality) to be able to form an advanced tumor. The acquisition of cellular imortality is linked to the reactivation of telomerase, an enzyme that has the potential to overcome the DNA end replication problem that occurs during each round of cell división. [...]

Bellaterra : Universitat Autònoma de Barcelona, 2002
3 documentos

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.